Literature DB >> 17568695

Melatonin attenuates the development of antinociceptive tolerance to delta-, but not to mu-opioid receptor agonist in mice.

Xu Dai1, Shi-gang Cui, Shi-rong Li, Qiang Chen, Rui Wang.   

Abstract

The effects of melatonin (Mel) on the development of tolerance to antinociceptive actions induced by mu- and delta-opioid receptor agonists were determined in male Kunming mice. In the mouse tail-flick tests, selective mu and delta receptor agonists were repeatedly administered to mice supraspinally (intracerebroventricularly, i.c.v.) in the absence or presence of melatonin. Administration of endomorphin-1 (EM-1, a mu-opioid receptor agonist) or deltorphin I (del I, a delta-opioid receptor agonist) twice daily for 4 days produced antinociceptive tolerance compared with vehicle controls. Co-administration with melatonin prevented the development of tolerance to deltorphin I analgesia, and this effect was dose dependent. However, melatonin did not affect the development of antinociceptive tolerance to endomorphin-1. Additionally, the attenuation of deltorphin I tolerance by melatonin was reduced by chronic treatment with luzindole (luz), a selective antagonist on the MT(2) receptor subtype. Taken together, these data suggest that melatonin interferes with the neural mechanisms involved in the development of tolerance to delta-opioid agonist analgesia via its receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568695     DOI: 10.1016/j.bbr.2007.04.018

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  10 in total

1.  Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain.

Authors:  Chunqiu Chen; Jakub Fichna; Moshe Laudon; Martin Storr
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

2.  Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.

Authors:  Gianfranco Balboni; Stella Fiorini; Anna Baldisserotto; Claudio Trapella; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Severo Salvadori
Journal:  J Med Chem       Date:  2008-08-05       Impact factor: 7.446

3.  Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).

Authors:  Severo Salvadori; Stella Fiorini; Claudio Trapella; Frank Porreca; Peg Davis; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-12-23       Impact factor: 3.641

4.  The role of melatonin in anaesthesia and critical care.

Authors:  Madhuri S Kurdi; Tushar Patel
Journal:  Indian J Anaesth       Date:  2013-03

5.  Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction.

Authors:  Yao-Chang Chiang; Ruey-Yun Wang; Chieh-Liang Huang; Shue-Hwa Chen; Wen-Jing Ho; Hsien-Yuan Lane; Ing-Kang Ho; Hwei-Ting Yang; Wen-Lung Ma
Journal:  J Cell Mol Med       Date:  2017-07-12       Impact factor: 5.310

Review 6.  Role of Melatonin in the Regulation of Pain.

Authors:  Shanshan Xie; Wenguo Fan; Hongwen He; Fang Huang
Journal:  J Pain Res       Date:  2020-02-07       Impact factor: 3.133

7.  Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment.

Authors:  Chieh-Liang Huang; Yao-Chang Chiang; Wei-Chun Chang; Yu-Ting Su; Juan-Cheng Yang; Wei-Chung Cheng; Hsien-Yuan Lane; Ing-Kang Ho; Wen-Lung Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-05       Impact factor: 5.555

Review 8.  The Role of Nutrient Supplementation in the Management of Chronic Pain in Fibromyalgia: A Narrative Review.

Authors:  Hannah Waleed Haddad; Nikita Reddy Mallepalli; John Emerson Scheinuk; Pranav Bhargava; Elyse M Cornett; Ivan Urits; Alan David Kaye
Journal:  Pain Ther       Date:  2021-04-28

9.  Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial.

Authors:  Maryam Shokri; Firozeh Sajedi; Younes Mohammadi; Maryam Mehrpooya
Journal:  Eur J Clin Pharmacol       Date:  2021-06-13       Impact factor: 2.953

10.  A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.

Authors:  Karen M Barlow; Brian L Brooks; Frank P MacMaster; Adam Kirton; Trevor Seeger; Michael Esser; Susan Crawford; Alberto Nettel-Aguirre; Roger Zemek; Mikrogianakis Angelo; Valerie Kirk; Carolyn A Emery; David Johnson; Michael D Hill; Jeff Buchhalter; Brenda Turley; Lawrence Richer; Robert Platt; Jamie Hutchison; Deborah Dewey
Journal:  Trials       Date:  2014-07-07       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.